CMF
ABCL icon

Counterpoint Mutual Funds’s AbCellera Biologics ABCL Stock Holding History

Counterpoint Mutual Funds’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.63M Buy
+971,643
New +$4.75M 0.75% 22
2023
Q1 		– Sell
-15,625
Closed -$158K – 330
2022
Q4 		$158K Buy
+15,625
New +$180K 0.17% 42

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Counterpoint Mutual Funds's ABCL Position: Q2 2026 in Review

Counterpoint Mutual Funds opened a new position in AbCellera Biologics (ABCL) in Q2 2026: 971,643 shares worth $7.63M. The stake represents 0.75% of the portfolio and ranks #22 among its holdings. This is a return to the name: Counterpoint Mutual Funds previously reported a position in ABCL as recently as Q4 2022.

Counterpoint Mutual Funds first reported a position in ABCL in Q4 2022 and has held it in 2 quarters since. 151 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • Counterpoint Mutual Funds held 971,643 shares of AbCellera Biologics worth $7.63M as of Q2 2026.
  • AbCellera Biologics was a new Counterpoint Mutual Funds position in Q2 2026.
  • AbCellera Biologics made up 0.75% of Counterpoint Mutual Funds's portfolio in Q2 2026, its #22 holding.
  • Counterpoint Mutual Funds first reported a position in AbCellera Biologics in Q4 2022 and has held it in 2 quarters since.
  • 151 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Counterpoint Mutual Funds's 13F filing for Q2 2026, filed 20 Jul 2026.